Dirui Industrial Co.,Ltd. (300396.SZ)
CNY 13.0
(1.17%)
CNY 13.0
(1.17%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 288.83 Million CNY | -17.76% |
| 2022 | 311.39 Million CNY | 27.55% |
| 2021 | 268.47 Million CNY | -26.57% |
| 2020 | 365.85 Million CNY | -2.8% |
| 2019 | 384.53 Million CNY | 10.29% |
| 2018 | 347.64 Million CNY | 10.27% |
| 2017 | 313.12 Million CNY | 26.68% |
| 2016 | 249.39 Million CNY | 43.69% |
| 2015 | 167.52 Million CNY | 28.26% |
| 2014 | 131.48 Million CNY | 6.03% |
| 2013 | 120.66 Million CNY | 11.84% |
| 2012 | 107.95 Million CNY | 15.26% |
| 2011 | 97.18 Million CNY | 85.38% |
| 2010 | 52.25 Million CNY | 88.81% |
| 2009 | 27.47 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 37.93 Million CNY | -70.05% |
| 2024 Q3 | 33.78 Million CNY | -21.07% |
| 2024 Q1 | 152.33 Million CNY | 235.0% |
| 2023 Q1 | 85.92 Million CNY | -2.69% |
| 2023 Q3 | 80.1 Million CNY | -19.13% |
| 2023 Q2 | 99.05 Million CNY | 15.27% |
| 2023 FY | - CNY | -17.76% |
| 2023 Q4 | 21.5 Million CNY | -73.15% |
| 2022 Q3 | 75.28 Million CNY | -11.57% |
| 2022 Q2 | 85.13 Million CNY | 27.08% |
| 2022 FY | - CNY | 27.55% |
| 2022 Q4 | 88.3 Million CNY | 17.3% |
| 2022 Q1 | 66.99 Million CNY | 1.15% |
| 2021 Q2 | 55.9 Million CNY | -18.03% |
| 2021 Q1 | 68.2 Million CNY | 74.73% |
| 2021 FY | - CNY | -26.57% |
| 2021 Q4 | 66.23 Million CNY | 32.17% |
| 2021 Q3 | 50.11 Million CNY | -10.36% |
| 2020 Q2 | 89.21 Million CNY | 96.11% |
| 2020 Q4 | 39.03 Million CNY | -73.08% |
| 2020 Q3 | 145.01 Million CNY | 62.54% |
| 2020 FY | - CNY | -2.8% |
| 2020 Q1 | 45.49 Million CNY | -29.91% |
| 2019 Q4 | 64.9 Million CNY | -23.67% |
| 2019 FY | - CNY | 10.29% |
| 2019 Q3 | 85.03 Million CNY | -15.05% |
| 2019 Q2 | 100.1 Million CNY | 51.1% |
| 2019 Q1 | 66.25 Million CNY | 13.64% |
| 2018 Q2 | 92.67 Million CNY | 68.72% |
| 2018 Q1 | 54.92 Million CNY | -29.59% |
| 2018 FY | - CNY | 10.27% |
| 2018 Q4 | 58.29 Million CNY | -24.9% |
| 2018 Q3 | 77.63 Million CNY | -16.23% |
| 2017 FY | - CNY | 26.68% |
| 2017 Q1 | 37.33 Million CNY | -49.22% |
| 2017 Q2 | 94.07 Million CNY | 151.95% |
| 2017 Q3 | 60.51 Million CNY | -35.67% |
| 2017 Q4 | 78.01 Million CNY | 28.92% |
| 2016 Q3 | 40.71 Million CNY | -40.33% |
| 2016 FY | - CNY | 43.69% |
| 2016 Q1 | 27.36 Million CNY | -65.57% |
| 2016 Q2 | 68.22 Million CNY | 149.29% |
| 2016 Q4 | 73.53 Million CNY | 80.61% |
| 2015 Q3 | 22.64 Million CNY | -45.09% |
| 2015 Q4 | 79.49 Million CNY | 251.09% |
| 2015 Q2 | 41.23 Million CNY | 236.22% |
| 2015 Q1 | 12.26 Million CNY | -75.35% |
| 2015 FY | - CNY | 28.26% |
| 2014 Q2 | 33.56 Million CNY | 93.81% |
| 2014 Q1 | 17.31 Million CNY | -60.61% |
| 2014 Q4 | 49.76 Million CNY | 91.69% |
| 2014 Q3 | 25.96 Million CNY | -22.65% |
| 2014 FY | - CNY | 6.03% |
| 2013 Q3 | 30.75 Million CNY | 0.0% |
| 2013 FY | - CNY | 11.84% |
| 2013 Q4 | 43.96 Million CNY | 42.98% |
| 2012 FY | - CNY | 15.26% |
| 2011 FY | - CNY | 85.38% |
| 2010 FY | - CNY | 88.81% |
| 2009 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 1.86 Billion CNY | 84.473% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.84 Billion CNY | 89.853% |
| Beijing Strong Biotechnologies, Inc. | 697.99 Million CNY | 58.619% |
| Medicalsystem Biotechnology Co., Ltd. | 475.01 Million CNY | 39.194% |
| Maccura Biotechnology Co.Ltd | 651.98 Million CNY | 55.699% |
| Guangzhou Wondfo Biotech Co.,Ltd | 859.12 Million CNY | 66.38% |
| Guangdong Hybribio Biotech Co.,Ltd. | 236.08 Million CNY | -22.347% |
| BGI Genomics Co., Ltd. | 714.86 Million CNY | 59.595% |
| Amoy Diagnostics Co., Ltd. | 352.59 Million CNY | 18.083% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -59 Million CNY | 589.48% |